News | Cath Lab | August 17, 2016

Minnesota Hospital Receives Cath Lab Upgrades from Corindus, Acist

Robotic therapy, rapid exchange FFR and automated contrast delivery provide advanced workflow solutions at Fairview Southdale Hospital

Corindus Corpath, Acist Medical RXi and CVi, Fairview Southdale Hospital, Minnesota, cath lab

August 17, 2016 — Corindus Vascular Robotics Inc. and Acist Medical Systems Inc. are providing Fairview Southdale Hospital, Edina, Minn., with three technologies that improve workflow in the cardiac cath lab. This includes the CorPath System from Corindus, and Acist’s RXi and CVi technologies.

"I am excited to work with both companies to bring innovative solutions to the cath lab that enhance patient care," said Gregory Helmer, M.D., FACC, co-director of medical research, Fairview Southdale Hospital. "Rapid FFR and robotic PCI are significant contributions to PCI procedures and may improve safety, lesion assessment, and bring further precision to our interventional procedures."

The CorPath System is the first U.S. Food and Drug Administration (FDA)-cleared robotic-assisted system for percutaneous coronary intervention (PCI), offering robotic precision that may improve clinical outcomes and protection for physicians and staff from serious occupational hazards in the cath lab. The Acist RXi technology provides the reassurance of accurate and reliable fractional flow reserve (FFR) measurements and the advantages of Rapid Exchange technology. Acist CVi simplifies contrast injection for procedures while enhancing safety, efficiency, control and image quality.

For more information: www.corindus.com, www.acist.com

Related Content

Teleflex Launches Next-Generation Sympro Elite and Expro Elite Snares
Technology | Cath Lab | February 07, 2018
Teleflex Inc. has announced 510(k) clearance by the U.S. Food and Drug Administration (FDA) and U.S. commercial launch...
SCAI Advocacy Committee Highlights Reimbursement Reform Efforts in 2017
News | Cath Lab | January 30, 2018
The Society for Cardiovascular Angiography and Interventions (SCAI) highlighted the efforts of its Advocacy Committee...
IAC Releases Cardiovascular Catheterization Accreditation Program
News | Cath Lab | January 25, 2018
January 25, 2018 – The Intersocietal Accreditation Commission (IAC) announced the release of its Cardiovascular Cathe
Videos | Cath Lab | January 04, 2018
Bernadette Speiser, BSN, MSN, CCRN, RCIS, a cardiac cath/EP nurse at Palo Alto Veterans Hospital, Palo Alto, Calif.,
FDA Initiates Class I Recall of Sterilmed Reprocessed Agilis Steerable Introducer Sheath
News | Cath Lab | January 04, 2018
The U.S. Food and Drug Administration (FDA) announced a Class I recall of Sterilmed’s Agilis Steerable Introducer...
The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA atherectomy system. Athar Ansari, M.D.

The California Heart & Vascular Clinic in El Centro, Calif., treated the first post-FDA clearance patient with a DABRA system. 

Feature | Cath Lab | November 24, 2017 | Athar Ansari, M.D., FACC
As debates about the current state and future of healthcare rage in Congress, the media and healthcare settings acros
Videos | Cath Lab | November 08, 2017
Juan Granada, M.D., Cardiovascular Research Foundation president and chief executive officer, shares his insights on
Results of the ORBITA study found no difference in exercise time after six weeks in patients with stable angina who received percutaneous coronary intervention (PCI) versus a placebo treatment. TCT 2017
Feature | Cath Lab | November 06, 2017
November 6, 2017 – Results from ORBITA, a prospective multi-center randomized blinded placebo-controlled study, found
Culprit Lesion-Only PCI Improves Outcomes for Cardiogenic Shock Patients Compared to Multivessel PCI
News | Cath Lab | November 01, 2017
November 1, 2017 — Results from the prospective, randomized, multicenter CULPRIT-SHOCK trial found an initial strateg
Overlay Init